The closing of the transaction is expected to occur in the first quarter of 2003, subject to certain conditions.

Athena provides lab testing services in the field of neurology.

The proceeds from the sale will to go towards Elan's recovery plan.

Earlier this month, Elan agreed to sell the US, Canadian and Japanese rights to its antifungal treatment Abelcet to Enzon for $370m (€372m).

It also sold its cancer pain treatment, Actiq, to Cephalon for $50m (€50.2m).